title: In reply.
authors: Denver Public Health Department, Denver, CO USA. rreves@dhha.org.
authors: Randall R
authors: RR
authors: Reves
mesh_terms: D000995:Antitubercular Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D024881:Drug Resistance, Bacterial; D004977:Ethambutol / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007538:Isoniazid / Q000009:adverse effects*; D008297:Male; D011718:Pyrazinamide / Q000008:administration & dosage*; D012293:Rifampin / Q000008:administration & dosage*; D014376:Tuberculosis / Q000188:drug therapy*
chemical_list: D000995:Antitubercular Agents; D011718:Pyrazinamide; D004977:Ethambutol; D007538:Isoniazid; D012293:Rifampin